CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 93 enrolled
Drug / intervention
Duloxetinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02335346
NCT02335346Phase 3Completed
CompareCT.gov

An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Osteoarthritis and Knee Pain

Eli Lilly and Company·interventional·Posted Jan 9, 2015·Updated Sep 18, 2019

In Brief

A Phase 3 clinical trial evaluating Duloxetine for Osteoarthritis of the Knee. Completed, enrolled 93 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety and efficacy of duloxetine in participants with osteoarthritis and knee pain. The study will last for 1 year.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesJapan
CollaboratorsShionogi

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 9, 2015
Enrollment StartJan 1, 2015
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.5 years ago

Interventions

Duloxetinedrug

Administered orally